Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence
Among common inflammatory indices, SII demonstrated the strongest association with treatment response and prognosis in HER2-positive breast cancer. As an inexpensive, readily available biomarker, it may assist clinical risk stratification. However, given the retrospective design and substantial heterogeneity in treatment regimens, these findings should be interpreted cautiously and validated in prospective studies.
Authors
- Xuanlin Wu (ORCID: https://orcid.org/0009-0002-0343-2346)
- Jianhui Liu (ORCID: https://orcid.org/0000-0003-2331-5585)
- Longgui Xie
- Jiexu Liao
- Mankai Tang
- Jie Wang
- Siqi Wu
- Huawei Yang
Institutions
- Guangxi Medical University (CN)
- Tumor Hospital of Guangxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.3389/fimmu.2026.1751072
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
- Wu Jieping Medical Foundation